1-甲基-4-(4-甲基苯基)吡咯烷-2-酮 | 54520-29-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-甲基-4-(4-甲基苯基)吡咯烷-2-酮
• 英文名称: 1-Methyl-4-(p-tolyl)-pyrrolidon-(2)
• 英文别名: N-Methyl-4-p-tolyl-pyrrolidin-2-on；1-methyl-4-p-tolyl-pyrrolidin-2-one；1-Methyl-4-(4-methylphenyl)pyrrolidin-2-one；1-methyl-4-(4-methylphenyl)pyrrolidin-2-one
• CAS: 54520-29-5
• 化学式: C₁₂H₁₅NO
• 分子量: 189.257
• InChiKey: ZPWHBRLPHWKPBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 三氟乙酸 、 三乙基硅烷 作用下， 反应 2.0h， 生成 1-甲基-4-(4-甲基苯基)吡咯烷-2-酮
  参考文献：
  名称：

  Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase

  摘要：

  HIV-1 integrase catalyzes the insertion of viral DNA into the genome of the host cell. Integrase inhibitor N-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide selectively inhibits the strand transfer process of integration. 4-Substituted pyrrolidinones possessing various groups on the pyrrolidinone nitrogen were introduced at the 5-position of the naphthyridine scaffold. These analogs exhibit excellent activity against viral replication in a cell-based assay. The preparation of these compounds was enabled by a three-step, two-pot reaction sequence from a common butenolide intermediate. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.038

文献信息

• Urea derivative or pharmacologically acceptable salt thereof
  申请人：KYORIN PHARMACEUTICAL CO. LTD.

  公开号：US10029983B2

  公开（公告）日：2018-07-24

  Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有类似甲酰肽受体 1（FPRL1）激动剂作用的化合物。 本发明涉及通式（I）所代表的化合物或其药理学上可接受的盐。本发明还涉及一种含有通式（I）所代表的化合物或其药理学上可接受的盐的药物组合物。
• Aryl pyrrolidinones via radical 1,4-aryl migration and 5-endo-trig cyclisation of N-(2-bromoallyl)arylcarboxamides
  作者：Matthew J. Palframan、Kirill Tchabanenko、Jeremy Robertson

  DOI：10.1016/j.tetlet.2006.09.040

  日期：2006.11

  Radical reaction of a series of N-(2-bromoallyl)arylearboxamides led to the production of 4-arylpyrrolidin-2-ones and directly reduced materials in comparable yields. A cascade process, involving sequential 5-exo-trig spirocyclisation, beta-scission, and 5-endo-trig cyclisation of the resulting acyl radical, is proposed to explain the pyrrolidinone products. (c) 2006 Elsevier Ltd. All rights reserved.
• UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：KYORIN PHARMACEUTICAL CO., LTD

  公开号：US20170066718A1

  公开（公告）日：2017-03-09

  Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.
• US9822069B2
  申请人：——

  公开号：US9822069B2

  公开（公告）日：2017-11-21